Gregory Conn biography
Dr. Gregory L. Conn Ph.D. serves as Chief Scientific Officer of the Company. Dr. Conn was a founding member of the PDS team in 2005 as Chief Scientific Officer and continues to serve PDS in that role. He has more than 35 years of drug-development expertise, including development of antiviral and anticancer drugs through to commercialization. He is a graduate of the Albert Einstein College of Medicine, where he obtained both his M.S. and Ph.D., discovering novel angiogenic molecules in the human brain. Dr. Conn started his pharmaceutical career at Merck, Sharpe, and Dohme, where he continued his work on novel angiogenic factors, discovering and characterizing the VEGF family of growth factors, work which led to the development and commercialization of the anti-cancer drug Avastin. He was later a leading scientist at Regeneron Pharmaceuticals, where he established and headed various groups in the Cell and Molecular Biology and Drug Discovery departments. Dr. Conn subsequently became a Director in the Process Development department at Covance Biotechnology Services Inc., a contract research and development and drug manufacturing organization, where he supervised the analytical development teams responsible for drug characterization, method development and drug stability studies, and program teams responsible for developing drug manufacturing processes. Dr. Conn has expertise across all phases of the drug development process, including FDA and regulatory requirements, is the co-inventor of eight drug patents.
What is the salary of Gregory Conn?
As the Chief Scientific Officer of PDS Biotechnology, the total compensation of Gregory Conn at PDS Biotechnology is $668,954. There are 2 executives at PDS Biotechnology getting paid more, with Frank Bedu-Addo having the highest compensation of $2,583,760.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
How old is Gregory Conn?
Gregory Conn is 65, he's been the Chief Scientific Officer of PDS Biotechnology since 2019. There are 2 older and 12 younger executives at PDS Biotechnology. The oldest executive at PDS Biotechnology Corporation is Richard Sykes, 78, who is the Independent Director.
What's Gregory Conn's mailing address?
Gregory's mailing address filed with the SEC is C/O PDS BIOTECHNOLOGY CORPORATION, 25B VREELAND ROAD, SUITE 300, FLORHAM PARK, NJ, 07932.
Insiders trading at PDS Biotechnology
Over the last 5 years, insiders at PDS Biotechnology have traded over $0 worth of PDS Biotechnology stock and bought 54,275 units worth $476,657 . The most active insiders traders include Gregory Gene Freitag, James J Loughlin et Kamil Ali Jackson. On average, PDS Biotechnology executives and independent directors trade stock every 67 days with the average trade being worth of $126,706. The most recent stock trade was executed by Frank Bedu Addo on 2 December 2022, trading 219,535 units of PDSB stock currently worth $1,442,345.
What does PDS Biotechnology do?
pds biotechnology is a clinical stage biopharmaceutical company developing the next-generation of simpler, safer and more effective immunotherapies for cancer and infectious diseases. pds biotechnology’s proprietary versamune® platform vector is based on synthetic and biodegradable lipids which possess a very specific structure and positive charge. the lipids form nanoparticles which activate and are taken up very efficiently by the immune system. the therapeutic product consists of versamune® formulated with a harmless form of the protein or disease-causing agent associated with the particular disease (the antigen) which our immune systems can recognize and respond to. this antigen could be a unique protein expressed only in the cancer cells and not in healthy cells, or it could be a specific viral protein(s) from an infectious virus for example. pds is in the process of completing its first phase 1 human clinical trial in 2015 for pds0101, and has initiated design and preparati
What does PDS Biotechnology's logo look like?
PDS Biotechnology executives and stock owners
PDS Biotechnology executives and other stock owners filed with the SEC include:
-
Frank Bedu-Addo,
President, Chief Executive Officer, Director -
Dr. Frank K. Bedu-Addo Ph.D.,
Pres, CEO & Director -
Gregory Conn,
Chief Scientific Officer -
Lauren V. Wood M.D.,
Chief Medical Officer -
Dr. Gregory L. Conn,
Chief Scientific Officer -
Gregory Freitag,
Independent Director -
DeLyle Bloomquist,
Independent Director -
Stephen Glover,
Independent Chairman of the Board -
Richard Sykes,
Independent Director -
Otis Brawley,
Director -
Deanne Randolph,
Investor Relations -
Kamil Ali-Jackson,
Independent Director -
Ilian Iliev,
Director -
Lauren Wood,
Chief Medical Officer -
Michael King,
Interim Chief Financial Officer -
Janetta Trochimiuk,
Controller -
Dr. Mark Baxter Ph.D.,
Sr. VP of Global Quality -
Hillary Yegen,
VP of Legal -
Dr. Joe J. Dervan,
VP of R&D -
Matthew C. Hill CPA,
CFO & Principal Accounting Officer -
Matthew C Hill,
Chief Financial Officer -
James J Loughlin,
Director -
Voorhees Seth Van,
Chief Financial Officer -
Lars Boesgaard,
Chief Financial Officer -
Spencer D. Brown,
Senior VP, General Counsel -
Kirk V. Shepard,
Chief Medical Officer -
Stephan Toutain,
Chief Operations Officer